Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 1/20 | 0.42 |
| ▸ | SLC9A1 | P19634 | 6/20 | 0.41 |
| ▸ | PLAU | P00749 | 2/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 3/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | F7 | P08709 | 1/20 | 0.38 |
| ▸ | P4HB | P07237 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16494659 | 0.92 | HTR5A (0.42) | HTR5ASLC9A1PLAUIRAK4SCN9A | |
| SCHEMBL16502766 | 0.86 | SLC9A1 (0.44) | HTR5ASLC9A1HTR2BHTR7 | |
| SCHEMBL7920034 | 0.85 | HTR5A (0.46) | HTR5ASLC9A1PLAUHTR2BHTR7 | |
| SCHEMBL16502453 | 0.85 | SLC22A12 (0.47) | P4HB | |
| SCHEMBL7920216 | 0.84 | HTR5A (0.47) | HTR5ASLC9A1HTR2BHTR7 | |
| SCHEMBL7913855 | 0.84 | SLC9A1 (0.54) | HTR5ASLC9A1 | |
| SCHEMBL16502722 | 0.84 | HTR2B (0.45) | HTR5ASLC9A1HTR2BHTR7 | |
| SCHEMBL16502452 | 0.84 | PLAU (0.47) | PLAUIRAK4SCN9AP4HB | |
| SCHEMBL16502794 | 0.84 | SLC9A1 (0.45) | HTR5ASLC9A1HTR2BHTR7 | |
| SCHEMBL16509473 | 0.82 | HTR5A (0.48) | HTR5ASLC9A1HTR2BHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2011-12-15 | — | — | US | disclosed |
| EP-2394987-A1 | ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | HTR5A, HTR2A, HTR1A | HTR5A 1/4885SLC9A1 1256/4885PLAU 2773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.